AR039272A1 - Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion - Google Patents

Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion

Info

Publication number
AR039272A1
AR039272A1 ARP030101238A ARP030101238A AR039272A1 AR 039272 A1 AR039272 A1 AR 039272A1 AR P030101238 A ARP030101238 A AR P030101238A AR P030101238 A ARP030101238 A AR P030101238A AR 039272 A1 AR039272 A1 AR 039272A1
Authority
AR
Argentina
Prior art keywords
glycyl
group
glycine
liquid preparation
peptide
Prior art date
Application number
ARP030101238A
Other languages
English (en)
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR039272A1 publication Critical patent/AR039272A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una preparación líquida estable que comprende un derivado de camptotecina que se prepara uniendo un compuesto de la fórmula (1): donde R1 es un grupo alquilo inferior sustituido o insustituido, X1 es un grupo de la fórmula: -NHR2 (R2 es un átomo de hidrógeno o un grupo alquilo inferior) o un grupo hidroxi y Alk es un grupo alquileno de cadena lineal o ramificada opcionalmente interrumpida por un átomo de oxígeno, y un polisacarido que tiene grupos carboxilo a través de un aminoácido o un péptido, o una sal farmacéuticamente aceptable del mismo, que se ajusta a un valor pH de 5-8, o una composición farmacéutica estable producida por liofilización de dicha preparación líquida. Reivindicación 11: La preparación líquida de acuerdo con la reivindicación 1, donde R1 es un grupo alquilo inferior C1-6 insustituido, X1 es un grupo amino y Alk es un grupo alquileno C1-6 de cadena lineal no interrumpido opr un átomo de oxigeno, un polisacarido es un dextrano o pululano carboximetilado, y un péptido es un péptido que consiste en 2 - 5 aminoácidos. Reivindicación 12: La preparación líquida de acuerdo con la reivindicación 11, donde R1 es un grupo etilo, un grupo de la fórmula: X1-Alk-O- es un grupo 3-aminopropiloxi, y el compuesto de camptotecina [1] está unido en la posición 10 de un núcleo de comptotecina, el polisacárido es dextrano en el cual se introduce un grupo carboxilo, el péptido es glicil-glicil-L- o D-fenilalanil-glicina, glicil-glicina, glicil-glicil-glicina, glicil-glicil-glicil-glicina, glicil-glicil-glicil-glicil-glicina, L o D-fenilalanil-glicina y L- o D-leucilglicina.
ARP030101238A 2002-04-16 2003-04-09 Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion AR039272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16

Publications (1)

Publication Number Publication Date
AR039272A1 true AR039272A1 (es) 2005-02-16

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101238A AR039272A1 (es) 2002-04-16 2003-04-09 Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion

Country Status (21)

Country Link
US (1) US20050215485A1 (es)
EP (1) EP1501549A2 (es)
JP (1) JP3927954B2 (es)
KR (1) KR100700963B1 (es)
CN (1) CN100544769C (es)
AR (1) AR039272A1 (es)
AU (1) AU2003223120B2 (es)
BR (1) BR0309283A (es)
CA (1) CA2480425A1 (es)
HR (1) HRP20040894A2 (es)
ME (1) MEP31308A (es)
MX (1) MXPA04010178A (es)
MY (1) MY136696A (es)
NO (1) NO20044964L (es)
PL (1) PL371677A1 (es)
RS (1) RS91204A (es)
RU (1) RU2315623C2 (es)
TW (1) TW200306314A (es)
UA (1) UA77295C2 (es)
WO (1) WO2003086471A2 (es)
ZA (1) ZA200408008B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024923D1 (de) * 2004-02-13 2011-01-05 Yakult Honsha Kk Wässrige lösung mit einem camptothecin
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
RU2435586C2 (ru) 2005-07-14 2011-12-10 Веллстат Байолоджикс Корпорейшн Лечение рака с применением вирусов, фторпиримидинов и камптотецинов
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
AU2015369185B2 (en) 2014-12-26 2020-10-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
KR20180039628A (ko) 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
CN108697806A (zh) * 2016-03-01 2018-10-23 日本化药株式会社 含有喜树碱类高分子衍生物的药物制剂
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
AU2022396967A1 (en) * 2021-11-26 2024-06-13 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
MY136696A (en) 2008-11-28
CA2480425A1 (en) 2003-10-23
RU2004133349A (ru) 2005-05-27
AU2003223120A1 (en) 2003-10-27
CN1646172A (zh) 2005-07-27
BR0309283A (pt) 2005-02-15
JP3927954B2 (ja) 2007-06-13
MEP31308A (en) 2010-10-10
NO20044964L (no) 2004-11-15
RU2315623C2 (ru) 2008-01-27
KR20050000516A (ko) 2005-01-05
US20050215485A1 (en) 2005-09-29
AU2003223120B2 (en) 2006-10-05
PL371677A1 (en) 2005-06-27
EP1501549A2 (en) 2005-02-02
TW200306314A (en) 2003-11-16
ZA200408008B (en) 2005-06-13
KR100700963B1 (ko) 2007-03-28
AU2003223120A2 (en) 2003-10-27
RS91204A (en) 2006-12-15
JP2005523329A (ja) 2005-08-04
WO2003086471A3 (en) 2004-04-15
WO2003086471A2 (en) 2003-10-23
MXPA04010178A (es) 2005-06-08
CN100544769C (zh) 2009-09-30
HRP20040894A2 (en) 2005-10-31
UA77295C2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
AR039272A1 (es) Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion
MY116665A (en) Camptothecin derivatives
CN100411683C (zh) 含有生长素释放肽的药物组合物
ATE252601T1 (de) Lang wirkende insulinotrope peptide
NZ603900A (en) Subcutaneous anti-her2 antibody formulation
RU2001108569A (ru) Стабилизированная фармацевтическая композиция в лиофилизированной форме
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
KR940008681A (ko) 디클로페낙 염용 비경구 용액
KR970042553A (ko) 캠프토테신 유도체
IL148170A0 (en) Amino acid derivatives which influence the activity of dipeptidyl peptidase iv and pharmaceutical compositions containing the same
WO2001009163A3 (en) Improvement of peptide transport by conjugation with bile acids
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
WO1990008557A1 (en) Pharmaceutical formulations of plasminogen activator proteins
MY135646A (en) Indolyl derivatives
BRPI0606119B8 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
JPS6416724A (en) Stable and injectable vinca dimer salt solution
RU2006126708A (ru) Фармацевтическая композиция винфлунина, предназначенная для парентерального введения, способ получения и применения
KR950024769A (ko) 고농도 tcf 제제
TW200505429A (en) Pharmaceutical composition
MXPA01008349A (es) Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.
RU2006115581A (ru) Терапевтические композиции
GR3006982T3 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure